By Stephen Felix
The Caribbean Public Health Agency (CARPHA) recently launched its Antimicrobial Resistance Regional Referral Laboratory at its Saint Lucia campus. Backed by approximately USD 2.5 million in UK funding through the Fleming Fund, the facility introduces advanced diagnostic technologies to a region that has long needed them. It is a significant and welcome investment. CARPHA, representing a commitment to building the Caribbean’s capacity to detect and respond to one of the most serious public health threats.
But detection is only the beginning. The harder question, and the one that will ultimately determine whether the region can protect its populations, is what happens after the test result is generated.
A Growing Crisis, Already Unfolding in Our Hospitals
Simply put, antimicrobial resistance (AMR) occurs when bacteria, viruses, and other microorganisms build resistance to the medicines designed to treat them. Every time antibiotics are overused, misused, or used unnecessarily, the organisms they target have a chance to adapt and survive. Over time, the drugs we depend on most stop working.
This is not an abstract, future concern. It is already reshaping clinical reality across the Caribbean. Common infections such as pneumonia and urinary tract infections are becoming harder to treat as the drugs we have relied on for decades lose effectiveness. Amoxicillin, one of the most widely prescribed antibiotics in the region, is increasingly failing against pathogens that have evolved to resist it. The consequences are immediate: longer hospital stays, reliance on more last-resort medications, rising treatment costs, and, in the worst cases, infections that simply cannot be treated.
For a region of roughly 44 million people dispersed across dozens of island states, these risks are compounded by the fragmentation that defines Caribbean health systems. AMR is no longer just a clinical issue. It is a system-wide challenge that strains supply chains, distorts national health expenditure, and demands coordination among clinicians, pharmacists, microbiologists, and policymakers; coordination that our infrastructure currently does not adequately support.
At its Core, AMR is a Surveillance Problem
The new CARPHA laboratory will generate critical data: pathogen identifications, resistance profiles, and susceptibility patterns. This is essential work. But the value of that data depends entirely on what it connects to.
Resistance patterns vary by region, by facility, and by population. Detecting meaningful trends requires continuous tracking of prescriptions, treatment outcomes, and patient histories. This kind of longitudinal data can only exist when systems are interconnected. And across much of the Caribbean, systems are not connected.
Many laboratories in the region still operate without a Laboratory Information System. Where digital systems do exist, they are rarely connected to anything beyond their own walls. They do not connect to the hospital’s records, the pharmacy, or the public health agencies that need this information to act. Lab results sit in isolation, unlinked to the prescriptions that preceded them or the outcomes that followed. Paper-based records remain common, and real-time data sharing is the exception, not the rule.
The result is a landscape of blind spots. Resistance trends go undetected until they become crises. Outbreaks that could have been identified early are caught late. Clinicians treating patients across different facilities have no reliable way to access a complete medical history. This problem is particularly prevalent in island states, where patients frequently cross jurisdictional boundaries.
From Diagnostics to Intelligence
The CARPHA laboratory investment addresses a critical gap in diagnostic capacity. The next challenge is building the digital infrastructure that transforms diagnostics into actionable intelligence.
This means adopting interoperability standards such as FHIR that enable laboratory systems, electronic health records, pharmacies, and public health databases to exchange data seamlessly. It means establishing unified patient identification so that a single individual’s health record is coherent and complete regardless of where they seek care. One patient, one record sounds simple, but requires deliberate architectural decisions and regional consensus to implement.
It means enabling real-time clinical decision support, where AI-driven tools can flag resistance patterns, recommend evidence-based treatment protocols, and alert clinicians to emerging threats before they escalate. And it means creating the policy frameworks that govern
cross-border data sharing for AMR surveillance.
This is the work that Medial Health was created to advance. We are building an interoperable, FHIR-based digital health infrastructure designed for the specific realities of Caribbean health
systems. Our goal is to ensure that the data generated from clinical encounters and diagnostics flows to the people and systems that need it, when they need it. As we implement across islands, our vision for healthcare in the Caribbean is that of a connected, intelligence-driven digital health ecosystem, culminating in the development of a Caribbean Health Information Exchange (CHIE); where data from providers, public health agencies like Caribbean Public Health Agency, and patients themselves can be securely shared across borders to strengthen surveillance, improve care coordination, and enable real-time, data-driven decision-making.
A Test of Digital Maturity
AMR will be one of the defining tests of the Caribbean’s health systems over the coming decade. It will reveal whether we have built systems capable of proactive, intelligence-driven response — or whether we remain trapped in reactive cycles, responding to crises after the damage is done.
CARPHA’s laboratory in Saint Lucia is a meaningful step forward. It brings advanced diagnostic capability closer to the Eastern Caribbean states that need it most. But a laboratory, no matter how well-equipped, cannot fulfill its potential within a disconnected ecosystem.
The investment in diagnostics must be matched by investments in digital infrastructure, workforce training, data governance, and interoperable systems that turn isolated test results into regional health intelligence. This is not a secondary priority. It is the infrastructure that will determine whether the Caribbean can truly protect its populations at scale.
The equipment is in place. The partnerships are forming. Now the region needs connective tissue, the digital backbone that makes it all work.